Drug intelligence / Profile preview

recombinant herpes zoster vaccine with high-dose adjuvant

Development stage: Unknown
Lead developer: Shanghai Institute of Biological Products
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular Injection

Overview

Recombinant herpes zoster vaccine with high-dose adjuvant is a vaccine produced in Chinese Hamster Ovary (CHO) cells. It is designed to prevent herpes zoster (shingles) and is being evaluated for its safety and immunogenicity in healthy individuals aged 40 years and above. The high-dose adjuvant is included to enhance the immune response.

Beyond the preview

Go deeper on recombinant herpes zoster vaccine with high-dose adjuvant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant herpes zoster vaccine with high-dose adjuvant.

Explore the full profile